A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

Phase 2 Completed 86 enrolled Sanofi

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

Timeline

Start: 2023-06-06
Primary completion: 2024-08-22
Completion: 2025-01-09

Outcome

Met primary endpoint

registry analysis (other test); Period A: Placebo vs Period A: SAR442970; Median posterior RR difference 29 (90% CI 10 to 47) NCT05849922 ↗

registry analysis (other test); Period A: Placebo vs Period A: SAR442970; Pr[Diff > 0%](%) 99.3 NCT05849922 ↗

release “treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50)” sanofi.com ↗

Publications

Lin J, Radhakrishnan J. What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials? J Am Soc Nephrol. 2025 Feb 3;36(8):1652-1654. doi: 10.1681/ASN.0000000648. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brivekimig	Protein / enzyme biologic	150 mg/ml	—